Literature DB >> 19625280

Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease.

H Sokol1, V Polin, A Lavergne-Slove, Y Panis, X Treton, X Dray, Y Bouhnik, P Valleur, P Marteau.   

Abstract

BACKGROUND AND AIMS: A previous study suggested that the presence of myenteric plexitis in the proximal resection margins could be predictive of early endoscopic recurrence after ileocolonic or ileal resection for Crohn's disease (CD). The aim of the present study was to assess the predictive value of plexitis for early clinical CD recurrence.
METHODS: All consecutive patients with ileocolonic or ileal resection for active CD in Lariboisière Hospital (Paris) between 1995 and 2006 were included. Clinical, surgical, histological and follow-up data were extracted from medical charts. Early clinical recurrence was defined as the reappearance of CD clinical manifestations requiring a specific treatment within 2 years postsurgery. The proximal resection margin was analysed using haematein eosin saffron (HES) staining and immunochemistry targeting mastocytes (anti-CD117 antibody) and lymphocytes (anti-CD3 antibody). Eosinophils were detected by HES staining. Ten cases of ileocolonic resections for caecal carcinoma served as controls.
RESULTS: Data were available from 171 postoperative follow-up periods in 164 patients with CD. Early clinical recurrence of CD occurred in 28.1%. In multivariate analysis, factors associated with postoperative recurrence were active smoking (hazard ratio (HR) = 1.94; 95% CI 1.06 to 3.60; p = 0.033), submucosal plexitis with >or=3 mastocytes (HR = 1.87; 95% CI 1.00 to 3.46; p = 0.048) and a disease-free resection margin <5 cm (HR = 0.52; 95% CI 0.27 to 1.02; p = 0.059).
CONCLUSIONS: Submucosal plexitis is associated with early clinical recurrence and could be taken into account in studies searching for new treatment strategies in the immediate postoperative period.

Entities:  

Mesh:

Year:  2009        PMID: 19625280     DOI: 10.1136/gut.2009.177782

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  32 in total

Review 1.  Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases.

Authors:  Fernando Ochoa-Cortes; Fabio Turco; Andromeda Linan-Rico; Suren Soghomonyan; Emmett Whitaker; Sven Wehner; Rosario Cuomo; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

Review 2.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?

Authors:  Rish K Pai; Karel Geboes
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

Review 3.  State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.

Authors:  Dario Sorrentino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-07       Impact factor: 46.802

4.  Endoscopy-based management decreases the risk of postoperative recurrences in Crohn's disease.

Authors:  Anne-Laure Boucher; Bruno Pereira; Stéphanie Decousus; Marion Goutte; Felix Goutorbe; Anne Dubois; Johan Gagniere; Corinne Borderon; Juliette Joubert; Denis Pezet; Michel Dapoigny; Pierre J Déchelotte; Gilles Bommelaer; Anthony Buisson
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

5.  Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.

Authors:  Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Satya Kurada; Noam Harpaz; Paula Borralho; Reetesh K Pai; Rish K Pai; Robert Odze; Roger Feakins; Claire E Parker; Tran Nguyen; Vipul Jairath; Mark E Baker; David H Bruining; J G Fletcher; Brian G Feagan; Florian Rieder
Journal:  Gastroenterology       Date:  2019-08-30       Impact factor: 22.682

6.  Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection.

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Feza H Remzi; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2016-07-31       Impact factor: 2.571

Review 7.  The multifaceted mast cell in inflammatory bowel disease.

Authors:  Matthew J Hamilton; Sandra M Frei; Richard L Stevens
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 8.  The impact of smoking in Crohn's disease: no smoke without fire.

Authors:  Marian C Aldhous; J Satsangi
Journal:  Frontline Gastroenterol       Date:  2010-09-23

9.  Risk Stratification for Prevention of Recurrence of Postoperative Crohn's Disease.

Authors:  Shirley Cohen-Mekelburg; Yecheskel Schneider; Stephanie Gold; Ellen Scherl; Adam Steinlauf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

Review 10.  Prevention of post-operative recurrence of Crohn's disease.

Authors:  Byron Philip Vaughn; Alan Colm Moss
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.